This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v2.0 was used to generate the results found in this report.
-
Working with individual set: COADREAD-TP
-
Number of patients in set: 488
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:COADREAD-TP.final_analysis_set.maf
-
Blacklist used for this analysis: pancan_mutation_blacklist.v14.hg19.txt
-
Significantly mutated genes (q ≤ 0.1): 474
-
Mutations seen in COSMIC: 9998
-
Significantly mutated genes in COSMIC territory: 1678
-
Significantly mutated genesets: 3
-
Significantly mutated genesets: (excluding sig. mutated genes):0
-
Read 140 MAFs of type "Broad"
-
Read 266 MAFs of type "Baylor-Illumina"
-
Read 87 MAFs of type "Baylor-SOLiD"
-
Total number of mutations in input MAFs: 241105
-
After removing 2 blacklisted mutations: 241103
-
After removing 72 noncoding mutations: 241031
-
After collapsing adjacent/redundant mutations: 230471
-
Number of mutations before filtering: 230471
-
After removing 127 mutations outside patient set: 230344
-
After removing 6942 mutations outside gene set: 223402
-
After removing 1207 mutations outside category set: 222195
-
After removing 4238 "impossible" mutations in
-
gene-patient-category bins of zero coverage: 209681
type | count |
---|---|
De_novo_Start_InFrame | 20 |
De_novo_Start_OutOfFrame | 155 |
Frame_Shift_Del | 13132 |
Frame_Shift_Ins | 3998 |
In_Frame_Del | 1723 |
In_Frame_Ins | 596 |
Missense_Mutation | 136150 |
Nonsense_Mutation | 10627 |
Nonstop_Mutation | 45 |
Silent | 53959 |
Splice_Site | 1788 |
Translation_Start_Site | 2 |
Total | 222195 |
category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio |
---|---|---|---|---|---|---|
*CpG->T | 45076 | 647938249 | 7e-05 | 70 | 5.5 | 2.2 |
A->G | 27228 | 6470281486 | 4.2e-06 | 4.2 | 0.33 | 2.3 |
*Cp(A/C/T)->T | 19486 | 5814253842 | 3.4e-06 | 3.4 | 0.26 | 1.7 |
transver | 41220 | 12932473577 | 3.2e-06 | 3.2 | 0.25 | 5.1 |
indel+null | 30618 | 12932473577 | 2.4e-06 | 2.4 | 0.19 | NaN |
double_null | 1028 | 12932473577 | 7.9e-08 | 0.079 | 0.0062 | NaN |
Total | 164656 | 12932473577 | 0.000013 | 13 | 1 | 3.5 |
The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom). If the figure is unpopulated, then full coverage is assumed (e.g. MutSig CV doesn't use WIGs and assumes full coverage).
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Column Descriptions:
-
N = number of sequenced bases in this gene across the individual set
-
n = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
n1 = number of nonsilent mutations of type: *CpG->T
-
n2 = number of nonsilent mutations of type: A->G
-
n3 = number of nonsilent mutations of type: *Cp(A/C/T)->T
-
n4 = number of nonsilent mutations of type: transver
-
n5 = number of nonsilent mutations of type: indel+null
-
n6 = number of nonsilent mutations of type: double_null
-
p_classic = p-value for the observed amount of nonsilent mutations being elevated in this gene
-
p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene
-
p_cons = p-value for enrichment of mutations at evolutionarily most-conserved sites in gene
-
p_joint = p-value for clustering + conservation
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_classic | p_ns_s | p_clust | p_cons | p_joint | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | CDH1 | cadherin 1, type 1, E-cadherin (epithelial) | 1274697 | 99 | 86 | 72 | 21 | 10 | 41 | 13 | 12 | 22 | 1 | 4.11e-15 | 0.0013 | 7.6e-06 | 0.22 | 0.000012 | 0.000 | 0.000 |
2 | TMEM37 | transmembrane protein 37 | 255218 | 22 | 22 | 7 | 2 | 4 | 3 | 1 | 0 | 14 | 0 | 2.19e-13 | 0.28 | 1.4e-06 | 0.21 | 5.4e-06 | 0.000 | 0.000 |
3 | FAM123B | family with sequence similarity 123B | 1508599 | 65 | 60 | 49 | 7 | 5 | 10 | 3 | 6 | 41 | 0 | 2.22e-14 | 0.038 | 0.000089 | 0.82 | 0.00031 | 2.22e-16 | 1.56e-13 |
4 | TCF7L2 | transcription factor 7-like 2 (T-cell specific, HMG-box) | 889185 | 58 | 54 | 42 | 6 | 12 | 3 | 4 | 11 | 28 | 0 | 4.44e-15 | 0.0039 | 0.0004 | 0.2 | 0.0014 | 2.22e-16 | 1.56e-13 |
5 | TGIF1 | TGFB-induced factor homeobox 1 | 505617 | 27 | 25 | 14 | 0 | 0 | 0 | 0 | 4 | 22 | 1 | 2.77e-13 | 0.26 | 0.000023 | 1 | 0.000064 | 6.66e-16 | 1.56e-13 |
6 | APC | adenomatous polyposis coli | 4122017 | 683 | 404 | 385 | 192 | 18 | 173 | 50 | 79 | 209 | 154 | 1.000 | 0.0028 | 0 | 0.99 | 0 | <1.00e-15 | <1.56e-13 |
7 | TP53 | tumor protein p53 | 604338 | 435 | 321 | 222 | 78 | 130 | 92 | 48 | 74 | 87 | 4 | 5.88e-15 | 1.7e-08 | 0 | 0 | 0 | <1.00e-15 | <1.56e-13 |
8 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 341646 | 247 | 232 | 42 | 21 | 2 | 22 | 125 | 95 | 3 | 0 | 2.78e-15 | 4.1e-11 | 0 | 0 | 0 | <1.00e-15 | <1.56e-13 |
9 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 1486109 | 344 | 212 | 164 | 131 | 24 | 173 | 79 | 55 | 13 | 0 | 1.000 | 0.13 | 0 | 0 | 0 | <1.00e-15 | <1.56e-13 |
10 | SMAD4 | SMAD family member 4 | 820519 | 191 | 145 | 119 | 63 | 29 | 73 | 26 | 38 | 23 | 2 | 1.000 | 0.043 | 6.8e-06 | 7e-06 | 0 | <1.00e-15 | <1.56e-13 |
11 | FBXW7 | F-box and WD repeat domain containing 7 | 1253787 | 156 | 131 | 92 | 55 | 44 | 34 | 9 | 33 | 35 | 1 | 1.000 | 0.61 | 0 | 6.4e-06 | 0 | <1.00e-15 | <1.56e-13 |
12 | KIT | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | 1455331 | 161 | 112 | 120 | 69 | 17 | 100 | 20 | 18 | 6 | 0 | 1.000 | 0.51 | 2e-07 | 0.00074 | 0 | <1.00e-15 | <1.56e-13 |
13 | BRAF | v-raf murine sarcoma viral oncogene homolog B1 | 1075517 | 125 | 109 | 55 | 43 | 4 | 44 | 10 | 58 | 9 | 0 | 1.000 | 0.34 | 0 | 0 | 0 | <1.00e-15 | <1.56e-13 |
14 | NEFH | neurofilament, heavy polypeptide 200kDa | 869213 | 111 | 109 | 21 | 4 | 1 | 1 | 1 | 3 | 105 | 0 | 1.55e-15 | 0.91 | 0 | 0.77 | 0 | <1.00e-15 | <1.56e-13 |
15 | CTNNB1 | catenin (cadherin-associated protein), beta 1, 88kDa | 1162129 | 120 | 92 | 71 | 49 | 6 | 58 | 17 | 32 | 7 | 0 | 1.000 | 0.29 | 0 | 0.17 | 0 | <1.00e-15 | <1.56e-13 |
16 | EGFR | epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) | 1864993 | 115 | 83 | 97 | 52 | 21 | 51 | 17 | 22 | 4 | 0 | 1.000 | 0.81 | 0 | 0 | 0 | <1.00e-15 | <1.56e-13 |
17 | MUC2 | mucin 2, oligomeric mucus/gel-forming | 1580696 | 82 | 72 | 34 | 14 | 7 | 5 | 6 | 9 | 54 | 1 | 1.23e-14 | 0.7 | 0 | 1 | 0 | <1.00e-15 | <1.56e-13 |
18 | RP1L1 | retinitis pigmentosa 1-like 1 | 2322741 | 88 | 68 | 42 | 21 | 15 | 2 | 5 | 11 | 47 | 8 | 0.000171 | 0.88 | 0 | 1 | 0 | <1.00e-15 | <1.56e-13 |
19 | FMN2 | formin 2 | 1727170 | 77 | 67 | 43 | 19 | 8 | 8 | 4 | 13 | 44 | 0 | 5.18e-07 | 0.87 | 0 | 1 | 0 | <1.00e-15 | <1.56e-13 |
20 | ACVR2A | activin A receptor, type IIA | 769875 | 66 | 60 | 22 | 3 | 4 | 2 | 1 | 4 | 52 | 3 | 7.77e-15 | 0.27 | 0 | 0 | 0 | <1.00e-15 | <1.56e-13 |
21 | CRIPAK | cysteine-rich PAK1 inhibitor | 352654 | 71 | 60 | 27 | 7 | 5 | 11 | 2 | 8 | 37 | 8 | <1.00e-15 | 0.14 | 0 | 0.99 | 0 | <1.00e-15 | <1.56e-13 |
22 | OR6C76 | olfactory receptor, family 6, subfamily C, member 76 | 451906 | 61 | 60 | 5 | 0 | 0 | 1 | 2 | 1 | 57 | 0 | 6.77e-15 | 0.2 | 0 | 0.95 | 0 | <1.00e-15 | <1.56e-13 |
23 | LIG1 | ligase I, DNA, ATP-dependent | 1250846 | 61 | 59 | 13 | 9 | 3 | 54 | 1 | 1 | 2 | 0 | 1.94e-10 | 0.017 | 0 | 0.98 | 0 | <1.00e-15 | <1.56e-13 |
24 | TNFAIP6 | tumor necrosis factor, alpha-induced protein 6 | 414475 | 59 | 59 | 7 | 2 | 3 | 0 | 0 | 3 | 53 | 0 | 7.55e-15 | 0.65 | 0 | 1 | 0 | <1.00e-15 | <1.56e-13 |
25 | ADAM29 | ADAM metallopeptidase domain 29 | 1193978 | 65 | 56 | 32 | 15 | 28 | 6 | 4 | 8 | 19 | 0 | 0.991 | 0.44 | 0 | 1.2e-06 | 0 | <1.00e-15 | <1.56e-13 |
26 | CASP5 | caspase 5, apoptosis-related cysteine peptidase | 637599 | 56 | 55 | 15 | 3 | 3 | 5 | 1 | 4 | 43 | 0 | 4.77e-15 | 0.29 | 0 | 1 | 0 | <1.00e-15 | <1.56e-13 |
27 | PIK3R1 | phosphoinositide-3-kinase, regulatory subunit 1 (alpha) | 1113239 | 62 | 52 | 40 | 13 | 8 | 29 | 2 | 4 | 17 | 2 | 0.0128 | 0.029 | 0 | 0.14 | 0 | <1.00e-15 | <1.56e-13 |
28 | DDHD1 | DDHD domain containing 1 | 1111723 | 51 | 50 | 5 | 1 | 2 | 0 | 0 | 1 | 48 | 0 | 1.11e-15 | 0.56 | 0 | 1 | 0 | <1.00e-15 | <1.56e-13 |
29 | RNF145 | ring finger protein 145 | 981537 | 57 | 49 | 22 | 3 | 4 | 13 | 4 | 3 | 31 | 2 | 1.03e-14 | 0.017 | 0 | 1 | 0 | <1.00e-15 | <1.56e-13 |
30 | JAK2 | Janus kinase 2 (a protein tyrosine kinase) | 1670611 | 55 | 48 | 42 | 25 | 6 | 35 | 4 | 6 | 1 | 3 | 1.000 | 0.7 | 0 | 0.036 | 0 | <1.00e-15 | <1.56e-13 |
31 | TSHR | thyroid stimulating hormone receptor | 1185507 | 59 | 48 | 37 | 12 | 8 | 31 | 6 | 13 | 1 | 0 | 1.91e-05 | 0.019 | 0 | 2e-07 | 0 | <1.00e-15 | <1.56e-13 |
32 | RNF43 | ring finger protein 43 | 1063139 | 54 | 47 | 27 | 2 | 7 | 5 | 1 | 4 | 34 | 3 | 3.54e-11 | 0.084 | 0 | 0.14 | 0 | <1.00e-15 | <1.56e-13 |
33 | ARHGAP5 | Rho GTPase activating protein 5 | 2088276 | 51 | 45 | 23 | 2 | 4 | 26 | 3 | 3 | 15 | 0 | 9.76e-07 | 0.000017 | 0 | 0.16 | 0 | <1.00e-15 | <1.56e-13 |
34 | KRTAP10-7 | keratin associated protein 10-7 | 330364 | 44 | 45 | 5 | 1 | 0 | 1 | 0 | 1 | 42 | 0 | 4.66e-15 | 0.85 | 0 | 0.15 | 0 | <1.00e-15 | <1.56e-13 |
35 | KRTAP4-1 | keratin associated protein 4-1 | 117393 | 47 | 45 | 3 | 0 | 3 | 0 | 0 | 0 | 44 | 0 | 4.77e-15 | 1 | 0 | 0.51 | 0 | <1.00e-15 | <1.56e-13 |
In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.
rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q |
---|---|---|---|---|---|---|---|---|---|
1 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 344 | 220 | 296 | 107360 | 48747 | 0 | 0 |
2 | APC | adenomatous polyposis coli | 685 | 839 | 582 | 409432 | 12807 | 0 | 0 |
3 | ATM | ataxia telangiectasia mutated | 237 | 245 | 157 | 119560 | 307 | 0 | 0 |
4 | TP53 | tumor protein p53 | 437 | 824 | 437 | 402112 | 123325 | 0 | 0 |
5 | PTCH1 | patched homolog 1 (Drosophila) | 143 | 256 | 118 | 124928 | 227 | 0 | 0 |
6 | RB1 | retinoblastoma 1 (including osteosarcoma) | 139 | 267 | 122 | 130296 | 306 | 0 | 0 |
7 | KIT | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | 161 | 240 | 105 | 117120 | 6849 | 0 | 0 |
8 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 333 | 767 | 323 | 374296 | 4779 | 0 | 0 |
9 | NF1 | neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) | 138 | 285 | 114 | 139080 | 200 | 0 | 0 |
10 | EGFR | epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) | 115 | 293 | 93 | 142984 | 1342 | 0 | 0 |
Note:
n - number of (nonsilent) mutations in this gene across the individual set.
cos = number of unique mutated sites in this gene in COSMIC
n_cos = overlap between n and cos.
N_cos = number of individuals times cos.
cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.
p = p-value for seeing the observed amount of overlap in this gene)
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | SA_G1_AND_S_PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. | ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 | 15 | ARF1(1), CCND1(2), CDK2(5), CDK4(4), CDKN1A(2), CDKN1B(6), CDKN2A(9), CFL1(2), E2F2(7), MDM2(11), NXT1(5), PRB1(5), TP53(435) | 5266161 | 494 | 339 | 277 | 99 | 140 | 106 | 56 | 85 | 103 | 4 | 1.1e-08 | <1.00e-15 | <6.16e-13 |
2 | RNAPATHWAY | dsRNA-activated protein kinase phosphorylates elF2a, which generally inhibits translation, and activates NF-kB to provoke inflammation. | CHUK, DNAJC3, EIF2S1, EIF2S2, MAP3K14, NFKB1, NFKBIA, PRKR, RELA, TP53 | 9 | CHUK(27), DNAJC3(4), EIF2S1(3), EIF2S2(2), MAP3K14(6), NFKB1(11), NFKBIA(1), RELA(10), TP53(435) | 6724417 | 499 | 337 | 280 | 92 | 151 | 110 | 54 | 83 | 97 | 4 | 6.1e-10 | 3.55e-15 | 1.09e-12 |
3 | TERTPATHWAY | hTERC, the RNA subunit of telomerase, and hTERT, the catalytic protein subunit, are required for telomerase activity and are overexpressed in many cancers. | HDAC1, MAX, MYC, SP1, SP3, TP53, WT1, ZNF42 | 7 | HDAC1(5), MAX(5), MYC(5), SP1(7), SP3(13), TP53(435), WT1(32) | 4783475 | 502 | 339 | 279 | 108 | 144 | 114 | 63 | 83 | 94 | 4 | 3.5e-09 | 5.66e-15 | 1.16e-12 |
4 | TCRMOLECULE | T Cell Receptor and CD3 Complex | CD3D, CD3E, CD3G, CD3Z, TRA@, TRB@ | 3 | CD3D(5), CD3E(2), CD3G(16) | 845905 | 23 | 21 | 8 | 3 | 1 | 5 | 2 | 0 | 15 | 0 | 0.46 | 0.0456 | 1.000 |
5 | HSA00472_D_ARGININE_AND_D_ORNITHINE_METABOLISM | Genes involved in D-arginine and D-ornithine metabolism | DAO | 1 | DAO(11) | 513817 | 11 | 11 | 11 | 1 | 9 | 0 | 1 | 1 | 0 | 0 | 0.11 | 0.152 | 1.000 |
6 | HSA00785_LIPOIC_ACID_METABOLISM | Genes involved in lipoic acid metabolism | LIAS, LIPT1, LOC387787 | 2 | LIAS(9), LIPT1(13) | 1090040 | 22 | 19 | 17 | 1 | 0 | 3 | 2 | 6 | 11 | 0 | 0.13 | 0.217 | 1.000 |
7 | APOPTOSIS_GENMAPP | APAF1, BAK1, BCL2L7P1, BAX, BCL2, BCL2L1, BID, BIRC2, BIRC3, BIRC4, CASP2, CASP3, CASP6, CASP7, CASP8, CASP9, CYCS, FADD, FAS, FASLG, GZMB, IKBKG, JUN, MAP2K4, MAP3K1, MAP3K14, MAPK10, MCL1, MDM2, MYC, NFKB1, NFKBIA, PARP1, PRF1, RELA, RIPK1, TNF, TNFRSF1A, TNFRSF1B, TNFSF10, TP53, TRADD, TRAF1, TRAF2 | 41 | APAF1(27), BAK1(2), BAX(16), BCL2(2), BCL2L1(1), BID(2), BIRC2(7), BIRC3(18), CASP2(8), CASP3(4), CASP6(3), CASP7(3), CASP8(20), CASP9(6), CYCS(1), FADD(1), FAS(9), FASLG(3), GZMB(5), IKBKG(2), JUN(2), MAP2K4(36), MAP3K1(21), MAP3K14(6), MAPK10(18), MDM2(11), MYC(5), NFKB1(11), NFKBIA(1), PARP1(17), PRF1(8), RELA(10), RIPK1(7), TNF(2), TNFRSF1A(4), TNFRSF1B(1), TNFSF10(3), TP53(435), TRAF1(7), TRAF2(8) | 24988324 | 753 | 380 | 494 | 173 | 201 | 152 | 89 | 140 | 165 | 6 | 2.8e-08 | 0.620 | 1.000 | |
8 | INOSITOL_METABOLISM | ALDH6A1, ALDOA, ALDOB, ALDOC, TPI1 | 5 | ALDH6A1(6), ALDOA(2), ALDOB(16), ALDOC(3), TPI1(3) | 2558746 | 30 | 28 | 26 | 3 | 6 | 6 | 2 | 15 | 1 | 0 | 0.027 | 0.677 | 1.000 | |
9 | SA_BONE_MORPHOGENETIC | Bone morphogenetic protein binds to its receptor to induce ectopic bone formation and promote development of the viscera. | BMP1, BMPR1A, BMPR1B, BMPR2, MADH1, MADH4, MADH6 | 4 | BMP1(17), BMPR1A(18), BMPR1B(15), BMPR2(49) | 4293349 | 99 | 71 | 82 | 16 | 21 | 16 | 5 | 21 | 26 | 10 | 0.039 | 0.689 | 1.000 |
10 | HSA00031_INOSITOL_METABOLISM | Genes involved in inositol metabolism | ALDH6A1, TPI1 | 2 | ALDH6A1(6), TPI1(3) | 1063963 | 9 | 9 | 9 | 1 | 0 | 1 | 1 | 7 | 0 | 0 | 0.31 | 0.788 | 1.000 |
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | HSA00472_D_ARGININE_AND_D_ORNITHINE_METABOLISM | Genes involved in D-arginine and D-ornithine metabolism | DAO | 1 | DAO(11) | 513817 | 11 | 11 | 11 | 1 | 9 | 0 | 1 | 1 | 0 | 0 | 0.11 | 0.15 | 1 |
2 | HSA00785_LIPOIC_ACID_METABOLISM | Genes involved in lipoic acid metabolism | LIAS, LIPT1, LOC387787 | 2 | LIAS(9), LIPT1(13) | 1090040 | 22 | 19 | 17 | 1 | 0 | 3 | 2 | 6 | 11 | 0 | 0.13 | 0.22 | 1 |
3 | HSA00031_INOSITOL_METABOLISM | Genes involved in inositol metabolism | ALDH6A1, TPI1 | 2 | ALDH6A1(6), TPI1(3) | 1063963 | 9 | 9 | 9 | 1 | 0 | 1 | 1 | 7 | 0 | 0 | 0.31 | 0.79 | 1 |
4 | BBCELLPATHWAY | Fas ligand expression by T cells induces apoptosis in Fas-expressing, inactive B cells. | CD28, CD4, HLA-DRA, HLA-DRB1, TNFRSF5, TNFRSF6, TNFSF5, TNFSF6 | 3 | CD28(5), CD4(4), HLA-DRB1(7) | 1196858 | 16 | 14 | 15 | 7 | 2 | 0 | 2 | 5 | 5 | 2 | 0.94 | 0.87 | 1 |
5 | FLUMAZENILPATHWAY | Flumazenil is a benzodiazepine receptor antagonist that may induce protective preconditioning in ischemic cardiomyocytes. | GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GPX1, PRKCE, SOD1 | 9 | GABRA1(19), GABRA2(17), GABRA3(7), GABRA4(22), GABRA5(21), GABRA6(22), GPX1(5), PRKCE(6) | 5195954 | 119 | 86 | 107 | 26 | 31 | 17 | 14 | 40 | 17 | 0 | 0.0067 | 0.9 | 1 |
6 | HSA00830_RETINOL_METABOLISM | Genes involved in retinol metabolism | ALDH1A1, ALDH1A2, BCMO1, RDH5 | 4 | ALDH1A1(12), ALDH1A2(17), BCMO1(5), RDH5(2) | 2727712 | 36 | 33 | 35 | 8 | 10 | 8 | 5 | 9 | 4 | 0 | 0.12 | 0.96 | 1 |
7 | HSA00643_STYRENE_DEGRADATION | Genes involved in styrene degradation | FAH, GSTZ1, HGD | 3 | FAH(4), GSTZ1(5), HGD(6) | 1586183 | 15 | 13 | 14 | 4 | 1 | 3 | 5 | 4 | 2 | 0 | 0.28 | 0.96 | 1 |
8 | TCRMOLECULE | T Cell Receptor and CD3 Complex | CD3D, CD3E, CD3G, CD3Z, TRA@, TRB@ | 2 | CD3D(5), CD3E(2) | 572147 | 7 | 7 | 4 | 3 | 0 | 5 | 1 | 0 | 1 | 0 | 0.67 | 0.97 | 1 |
9 | INOSITOL_METABOLISM | ALDH6A1, ALDOA, ALDOB, ALDOC, TPI1 | 4 | ALDH6A1(6), ALDOA(2), ALDOC(3), TPI1(3) | 2014016 | 14 | 13 | 14 | 1 | 4 | 1 | 1 | 8 | 0 | 0 | 0.091 | 0.97 | 1 | |
10 | 1_2_DICHLOROETHANE_DEGRADATION | ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, ALDH3A2, ALDH9A1 | 7 | ALDH1A1(12), ALDH1A2(17), ALDH1A3(20), ALDH1B1(10), ALDH3A1(7), ALDH3A2(11), ALDH9A1(4) | 4842817 | 81 | 59 | 74 | 12 | 27 | 13 | 11 | 20 | 10 | 0 | 0.0011 | 0.97 | 1 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.